Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells

Journal of Nutritional Biochemistry

Volumn 19, Issue 7, 2008, Pages 448-458

  Hong, Mee Young ^a   Seeram, Navindra P ^a   Zhang, Yanjun ^a   Heber, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chinese red yeast rice; Cholesterogenesis; Colon cancer; Lovastatin; Monacolins; Pigment

Indexed keywords

HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CRYSTALLIZATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PURIFICATION; RICE; SIGNAL TRANSDUCTION; TUMOR GROWTH; YEAST;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCOMYCOTA; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DIETARY SUPPLEMENTS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LOVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

MONASCUS PURPUREUS;

EID: 44649156402     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2007.05.012     Document Type: Article

References (53)

1. Ma J., Li Y., Ye Q., Li J., Hua Y., Ju D., et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48 (2000) 5220-5225
2. Ying SS, T'ien Jung, K'ai Wu-Sun ET, Sun SC, transl. Chinese technology in the seventeenth century. London: Pennsylvania State University Press; 1966. p. 292--4.
3. Haval R.J. Dietary supplement or drug? The case of cholestin. Am J Clin Nutr 69 (1999) 175-176
4. Stuart M.D. Chinese material medica: vegetable kingdom (1979), Southern Materials Center, Taipai (Republic of China)
5. Van T.P. Monascus, genre nouveau de l'ordre des Ascomycetes. Bull Soc Fr 31 (1884) 226-231
6. Went F.A.F.C. Monascus purpureus le champignon de l'angquac une nouvelle thelebolee. Ann Soc Nat Bot 8 (1895) 1-17
7. Martinkova L., Patakova-Juzlova P., Krent V., Kucerova Z., Havlicek V., Olsovsky P., et al. Biological activities of oligoketide pigments of Monascus purpureus. Food Addit Contam 16 (1999) 15-24
8. Heber D., Lembertas A., Lu Q.-Y., Bowerman S., and Go V.L.W. An analysis of nice proprietary Chinese Red Yeast Rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med 7 (2001) 133-139
9. Retterstol K., Stugaard M., Gorbitz C., and Ose L. Results of intensive long-term treatment of familial hypercholesterolemia. Am J Cardiol 78 (1996) 1369-1374
10. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 5 (2005) 930-942
11. Lewis-Barned N.J., and Ball M.J. Beneficial effect of simvastatin in patients with drug resistant familial hypercholesterolaemia. N Z Med J 105 (1992) 284-286
12. Jenkins D.J., Kendall C.S., Marchie A., Faulkner D.A., Wond J.M., de Souza R., et al. Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein. JAMA 290 (2003) 502-510
13. Wei W., Li C., Want Y., Su H., Zhu J., and Kritchevsky D. Hypolipidemic and anti-atherogenic effects of long-term cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits. J Nutr Biochem 14 (2003) 314-318
14. Lee C.L., Tsai T.Y., Wang J.J., and Pan T.M. In vivo hypolipidemic effects and safety of low dosage Monascus powder in a hamster model of hyperlipidemia. Appl Microbiol Biotechnol 705 (2006) 533-540
15. Jeon T., Hwang S.G., Hirai S., Matsui T., Yano H., Kawada T., et al. Red yeast rice extracts suppress adipogenesis by down-regulating adipogenic transcription factors and gene expression in 3T3-L1 cells. Life Sci 75 (2004) 3195-3203
16. Lin C.C., Li T.C., and Lai M.M. Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 153 (2005) 679-686
17. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 339 (1992) 1154-1156
18. Hentosh P., Yuh S.H., Elson C.E., and Peffley D.M. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 32 (2001) 154-166
19. Notarnicola M., Messa C., Pricci M., Guerra V., Altomare D.F., Montemurro S., et al. Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res 24 (2004) 3837-3842
20. Caruso M.G., Notarnicola M., Cavallini A., and Di Leo A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer. J Gastroenterol 37 (2002) 504-508
21. Agarwal B., Halmos B., Feoktistov A.S., Protiva P., Ramey W.G., Chen M., et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 23 (2002) 521-528
22. 1 cyclin-dependent kinases. J Biol Chem 278 (2003) 43586-43594
23. Lin W.Y., Song C.Y., and Pan T.M. Proteomic analysis of Caco-2 cells treated with monacolin K. J Agric Food Chem 54 (2006) 6192-6200
24. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and the risk of colorectal cancer. N Engl J Med 352 (2005) 2184-2192
25. Heber D., Yip I., Ashley J.M., Elashoff D.A., Elashoff R.M., and Go V.L. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69 (1999) 231-236
26. Li Z., Seeram N.P., Lee R., Thames G., Minutti C., Wang H.J., et al. Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers. J Altern Complement Med 11 (2005) 1031-1038
27. Reddy B.S., Wang C.X., Kong A.N., Khor T.O., Zheng X., Steele V.E., et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66 (2006) 4542-4546
28. Swamy M.V., Patlolla J.M., Steele V.E., Kopelovich L., Reddy B.S., and Rao C.V. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 66 (2006) 7370-7377
29. Naito Y., Katada K., Takagi T., Tsuboi H., Isozaki Y., Handa O., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med 17 (2006) 997-1004
30. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
31. Pedersen T.R., Berg K., Cook T.J., Faergeman O., Haghfelt T., Kjekshus J., et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 156 (1996) 2085-2092
32. Chen F.C., Manchand P.S., and Whalley W.B. The chemistry of fungi: LXIV. The structure of monascin: the relative stereochemistry of the azaphilones. J Chem Soc 21 (1971) 3577-3579
33. Manchand P.S., Whally W.B., and Chen F.C. Isolation and structure of ankaflavin. Phytochemistry 12 (1973) 2531-2532
34. Kuromo M., Nakanishi K., Shindo K., and Tada M. Biosynthesis of monascorubrin and monascoflavin. Chem Pharm Bull (Tokyo) 11 (1963) 358-362
35. Hadfield J.R., Holker J.S.E., and Stanway D.N. The biosynthesis of fungal metabolites: Part II. The β-oxo-lactone equivalences in rubropunctatin and monascorubrin. J Chem Soc 19 (1967) 751-755
36. Fowell A.D.G., Robertson A., and Whalley W.B. Monascorubramin. J Chem Soc 5 (1956) 27-35 [special publication]
37. Kim C., Jung H., Kim Y.O., and Shin C.S. Antimicrobial activities of amino acid derivatives of Monascus pigments. FEMS Microbiol Lett 264 (2006) 117-124
38. Journoud M., and Jones P.J. Red yeast rice: a new hypolipidemic drug. Life Sci 74 (2004) 2675-2683
39. Yasukawa K., Takahashi M., Natori S., Kawai K., Yamazaki M., Takeuchi M., et al. Azaphilones inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mice. Oncology 51 (1994) 108-112
40. Yasukawa K., Takahashi M., Yamanouchi S., and Takido M. Inhibitory effect of oral administration of Monascus pigment on tumor promotion in two-stage carcinogenesis in mouse skin. Oncology 53 (1996) 247-249
41. Muller C., Kiehl M.G., van de Loo J., and Koch O.M. Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int J Mol Med 3 (1999) 63-68
42. Ahn K.S., Sethi G., and Aggarwal B.B. Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol 178 (2007) 2507-2516
43. Lee J.Y., Kim J.S., Kim J.M., Kim N., Jung H.C., and Song I.S. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 7 (2007) 241-248
44. Mantha A.J., Hanson J.E.L., Goss G., Lagarde A.E., Lorimer I.A., and Dimitroulakos J. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11 6 (2005) 2398-2407
45. Mascaro C., Ortiz J.A., Ramos M.M., Haro D., and Hegardt F.G. Sterol regulatory element binding protein-mediated effect of fluvastatin on cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase transcription. Arch Biochem Biophys 374 (2000) 286-292
46. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131
47. Naito Y., Katada K., Takagi T., Tsuboi H., Isozaki Y., Handa O., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med 17 (2006) 997-1004
48. Musial J., Undas A., Gajewski P., Jankowski M., Sydor W., and Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 77 (2001) 247-253
49. Devaraj S., Chan E., and Jialal I. Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91 (2006) 4489-4496
50. Sinicrope F.A. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 45 (2006) 447-454
51. Feleszko W., Jalili A., Olszewska D., Mlynarcznuk I., Grzela T., Giermasz A., et al. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 9 (2002) 879-885
52. Swamy M.V., Patlolla J.M., Steele V.E., Kopelovich L., Reddy B.S., and Rao C.V. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 66 (2006) 2370-2377
53. Palozza P., Serini S., Maggiano N., Tringali G., Navarra P., Ranelletti F.O., et al. Beta-carotene downregulates the steady-state and heregulin-alpha-induced COX-2 pathways in colon cancer cells. J Nutr 135 (2005) 129-136